Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy
NCT ID NCT07520045
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two eye injections—faricimab and a biosimilar version of ranibizumab—in 100 adults with diabetic retinopathy. Researchers will use eye scans (OCT and OCT angiography) to see which drug leads to better early changes in the retina after three monthly doses. The goal is to find imaging markers that predict who responds best to each treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
faricimab and biosimilar ranibizumab (eye injections)
What this could lead to
If successful, this study could help doctors choose the best eye injection for each patient with diabetic retinopathy based on early imaging signs.
What could go wrong
This is a small, early-stage study (100 people) that only looks at imaging changes after three doses. It does not test long-term vision outcomes or safety, so results may not change practice directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY (DR) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Osijek
RECRUITINGOsijek, 31000, Croatia
Contact Phone: •••-•••-•••• Email: •••••@•••••